| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Fraxinellone targets voltage-dependent calcium channels. By blocking these channels, it exerts vasorelaxing effects. It is also a PD-L1 inhibitor. It inhibits HIF-1α synthesis without affecting its degradation. This mechanism contributes to its potential for cancer immunity. Its antimicrobial and anti-inflammatory effects are mediated through other pathways.
|
|---|---|
| ln Vitro |
In A549 cells, fraxinellone (0-100 μM; 12 hours) lowers the proportion of PD-L1-positive cells from 20.4% to 11.4% [1].
In vitro, fraxinellone is a selective blocker of voltage-dependent Ca2+ channels. It has antimicrobial and anti-inflammatory activities. It inhibits HIF-1α synthesis. It has been shown to have neuroprotective effects. It also exhibits insecticidal activities, including feeding-deterrent and larvicidal effects. |
| ln Vivo |
Oral gavage of fraxinellone (30 and 100 mg/kg; every three days; 30 days) effectively reduced the amount of HIF-1α, pTyr705 STAT3, PD-L1, and VEGF-stained animals and suppressed tumor growth [1].
In vivo, fraxinellone has been reported to possess anti-inflammatory, neuroprotective, and vasorelaxing activities. It has potential for cancer immunity by targeting PD-L1. It is used as an insecticidal agent for crop protection. Its therapeutic potential is being investigated in various disease models. |
| Enzyme Assay |
In vitro receptor binding assays for fraxinellone measure its inhibition of voltage-dependent calcium channels. Its effects on PD-L1 expression can be assessed by Western blotting. Its anti-inflammatory activity can be assessed by measuring cytokine production.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: A549 cells Tested Concentrations: 0 μM, 10 μM, 30 μM, 100 μM Incubation Duration: 12 hrs (hours) Experimental Results: Inhibited the percent of PD-L1 positive cells. In vitro cell-based assays for fraxinellone involve treating cells with the compound and measuring its effects on calcium influx, cell viability, and inflammation. Its effects on PD-L1 expression and HIF-1α levels are assessed. Its neuroprotective effects are studied in neuronal cell cultures. |
| Animal Protocol |
Animal/Disease Models: BALB/c nude mice[1]
Doses: 30 and 100 mg/kg Route of Administration: po (oral gavage); 30 and 100 mg/kg; every three days; 30 days Experimental Results: Dramatically suppressed tumor growth. In vivo animal experiments for fraxinellone have been conducted in models of inflammation and cancer. Animals are treated with the compound, and its effects on tumor growth and inflammation are assessed. Its insecticidal activity is evaluated in agricultural settings. |
| ADME/Pharmacokinetics |
Fraxinellone has a molecular weight of 232.28 and a molecular formula of C14H16O3. It has a density of 1.2±0.1 g/cm3. It is a white to off-white solid. It is typically stored under recommended conditions for natural products.
|
| Toxicity/Toxicokinetics |
Fraxinellone is a natural compound and is generally considered to have a favorable safety profile. It is for research use only and is not intended for human use. Standard safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
Fraxinellone belongs to the 2-benzofuran class of compounds. It has been reported to exist in Raulinoa echinata, Fagaropsis glabra, and other organisms with relevant data.
Fraxinellone is a natural sesquiterpene lactone. It is a selective blocker of voltage-dependent Ca2+ channels. It has antimicrobial, anti-inflammatory, neuroprotective, and vasorelaxing activities. It is also a PD-L1 inhibitor. It exhibits insecticidal activities. |
| Molecular Formula |
C14H16O3
|
|---|---|
| Molecular Weight |
232.2750
|
| Exact Mass |
232.109
|
| CAS # |
28808-62-0
|
| PubChem CID |
124039
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
372.9±30.0 °C at 760 mmHg
|
| Melting Point |
116ºC
|
| Flash Point |
179.3±24.6 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.552
|
| LogP |
2.85
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C2C(=O)O[C@H]([C@@]2(CCC1)C)C3=COC=C3
|
| InChi Key |
XYYAFLHHHZVPRN-GXTWGEPZSA-N
|
| InChi Code |
InChI=1S/C14H16O3/c1-9-4-3-6-14(2)11(9)13(15)17-12(14)10-5-7-16-8-10/h5,7-8,12H,3-4,6H2,1-2H3/t12-,14+/m0/s1
|
| Chemical Name |
(3R,3aR)-3-(furan-3-yl)-3a,7-dimethyl-3,4,5,6-tetrahydro-2-benzofuran-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~430.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3051 mL | 21.5257 mL | 43.0515 mL | |
| 5 mM | 0.8610 mL | 4.3051 mL | 8.6103 mL | |
| 10 mM | 0.4305 mL | 2.1526 mL | 4.3051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
